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Accepted 10 June 2014A gastrointestinal stromal tumor (GIST) is a speciﬁc mesen-
chymal tumor of the gastrointestinal tract [1]. It is believed to
arise from the interstitial cells of Cajal [2]. A GIST can originate
anywhere in or near the gastrointestinal tract such as the
stomach, bowel, rectovaginal septum, and uterus [2e6]. It may
also present as a pelvic mass that mimics a gynecologic
neoplasm [3]. To date, only a few cases of GIST mimicking gy-
necologic tumors have been reported [2e6]. Most gynecologists
are likely to be unfamiliar with the clinical features and outcome
of a pelvic GIST. In this paper, we describe the clinical features,
treatment, and outcome of a pelvic GIST in a middle-aged
woman who was initially diagnosed with a possible ovarian
malignancy.
A 54-year-old woman, gravida 4, para 2, with type I neuroﬁ-
bromatosis presented at our hospital with abdominal distension
that deteriorated progressively in the months before her visit. Ul-
trasonography showed a solid right adnexal mass and minimal
ascites. Computed tomography (CT) conﬁrmed a 14-cm pelvic mass
containing cystic and solid components (Figure 1A), dilated bowel
loops, and left hydronephrosis. Laboratory data showed a low level
of serum hemoglobin (7 g/dL) and elevated level of serum cancer
antigen (CA) 125 (363.6 U/mL). Preoperative colonoscopy and
gastroscopy did not show any intraluminal mass and other tumor
markers; in particular, carcinoembryonic antigen and cancer anti-
gen 19-9 were within normal limits. We preoperatively suspected
an ovarian malignancy.* Corresponding author. Department of Obstetrics and Gynecology, Far Eastern
Memorial Hospital, Number 21, Section 2, Nanya South Road, Banqiao District, New
Taipei City, Taiwan.
E-mail address: smhsiao2@gmail.com (S.-M. Hsiao).
c These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.tjog.2014.06.004
1028-4559/Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. PublishedExploratory laparotomy was performed and a 14-cm necrotic
and semisolid tumor was found. It was densely adhered to the
uterine fundus and ileum. Frozen section pathological examination
revealed that the mass was a sarcoma. Total abdominal hysterec-
tomy, bilateral salpingo-oophorectomy, bilateral pelvic lymph node
dissection, and partial omentectomy were then performed with
segmental resection and reanastomosis of the ileum because of
tumor-related segmental stenosis. No residual tumor remained
after surgery.
The ﬁnal histopathologic examination showed that the tumor
was a malignant GIST (Figures 1B and 1C). The mitotic index of
the tumor was 5e10 per 50 high power ﬁelds. The tumor cells
stained positive for CD117 (diffuse), S-100 (focal), and vimentin,
and stained negative for actin and desmin. The patient received
imatinib (400 mg daily) during a 3.5-year follow-up period, and
her postoperative course was uneventful. The CA125 levels
declined after surgery (51.12 U/mL at 1 month postsurgery,
11.88 U/mL at 2 years postsurgery, and 10.37 U/mL at 3 years
postsurgery). At the 3.5-year follow up, there was no evidence of
recurrent GIST.
In this patient, our initial preoperative diagnosis of a possible
ovarian malignancy was incorrect. In general, it is often difﬁcult
preoperatively to diagnose GIST correctly because it is a rare
mesenchymal tumor that can occur anywhere in or near the
gastrointestinal tract. Imaging modalities such as CT, magnetic
resonance imaging, and ﬂuorine-18-ﬂuorodeoxyglucose positron
emission tomography are useful diagnostic and treatment eval-
uation tools for a suspected GIST. On CT, a large well-
circumscribed densely enhancing mass with an exophytic
growth pattern or ulceration suggests a diagnosis of GIST.
However, it may not be possible to differentiate GIST from other
pelvic neoplasms using CT alone. CT nonetheless can also be
useful in tracing the tumor pedicle and detecting hepatic or
peritoneal metastatic disease [7]. The combination of positron
emission tomography and CT may be optimal for the precise
delineation of the tumor and assessment of the patient's
response to therapy [7].
Complete resection remains the most effective treatment for
GIST [8], whereas retroperitoneal lymph node dissection is rec-
ommended in cases of ovarian cancer. In GIST, metastasis toby Elsevier Taiwan LLC. All rights reserved.
Figure 1. (A) The coronal computed tomography scan of the pelvis shows a dilated
loop of the jejunum with uneven wall thickening and an adjacent large, extramural,
necrotic pelvic mass (arrows). Histopathological examination shows (B) intersecting
fascicles of spindle tumor cells [hematoxylin and eosin (H&E) staining; magniﬁcation,
200] and (C) strongly positive immunohistochemical staining for CD 117 in the
spindle tumor cells (H&E staining; magniﬁcation, 200).
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routinely required [8]. Debulking surgery such as pelvic lymph
node dissection and partial omentectomy was performed in our
patient, although lymphadenectomy and partial omentectomy can
be omitted if the pathologic examination of a frozen tumor section
leads to a diagnosis of GIST.
A coordinated surgical approach that includes a gynecologist
and general surgeon should be considered in cases of pelvic GIST
with intestinal involvement. Imatinib remains the mainstay
adjuvant therapy for GIST after surgery [8]. In general, the
outcome of GIST is good. At 12 months posttreatment initiation,
71% of patients reportedly show no progression of disease and
the overall survival is 86%, even in patients with advanced GIST
[8]. Our patient had type I neuroﬁbromatosis. Gastrointestinal
stromal tumors are approximately 150 times more common in
patients with type I neuroﬁbromatosis than in the general pop-
ulation [9].
In conclusion, a pelvic GIST may mimic an ovarian neoplasm
but it requires a different surgical approach. A GIST is a rare
disorder and it should be included in the differential diagnosis
of a pelvic massdespecially in women with type I
neuroﬁbromatosis.Conﬂicts of interest
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